Published in Cell Cycle on September 14, 2012
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget (2014) 1.34
PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med (2015) 1.16
Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ (2013) 1.12
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A (2013) 1.11
Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Mol Aspects Med (2012) 1.11
Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep (2014) 1.09
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One (2013) 1.06
Resistance to PARP-Inhibitors in Cancer Therapy. Front Pharmacol (2013) 0.99
The Promise of Proteomics for the Study of ADP-Ribosylation. Mol Cell (2015) 0.98
BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol (2014) 0.95
Regulation and roles of Cdc7 kinase under replication stress. Cell Cycle (2014) 0.92
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS One (2014) 0.91
Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res (2014) 0.91
Rad51 supports triple negative breast cancer metastasis. Oncotarget (2014) 0.89
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget (2013) 0.88
New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol (2013) 0.86
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. Oncotarget (2014) 0.85
Autoimmune response to PARP and BRCA1/BRCA2 in cancer. Oncotarget (2015) 0.83
PARI overexpression promotes genomic instability and pancreatic tumorigenesis. Cancer Res (2013) 0.82
UbcH7 regulates 53BP1 stability and DSB repair. Proc Natl Acad Sci U S A (2014) 0.80
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget (2015) 0.79
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Cancer Res (2014) 0.78
Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line. BMC Cancer (2014) 0.77
BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci Rep (2015) 0.77
Predicting PARP inhibitor sensitivity and resistance. Cell Cycle (2012) 0.77
Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells. J Hematol Oncol (2015) 0.76
Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers. Oncogene (2016) 0.76
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther (2013) 0.76
PARP1 Differentially Interacts with Promoter region of DUX4 Gene in FSHD Myoblasts. J Genet Syndr Gene Ther (2016) 0.75
Enhanced killing of SCC17B human head and neck squamous cell carcinoma cells after photodynamic therapy plus fenretinide via the de novo sphingolipid biosynthesis pathway and apoptosis. Int J Oncol (2015) 0.75
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer (2017) 0.75
Addicted to PAR? A closer look at PARP inhibitor sensitivity. Cell Cycle (2012) 0.75
What a 'Ku'incidence!: parallel discoveries of a new DNA repair factor. Cell Death Differ (2015) 0.75
A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining. Open Biol (2016) 0.75
PARP inhibitors and more. J Turk Ger Gynecol Assoc (2015) 0.75
Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) (2016) 0.75
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny (2017) 0.75
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep (2017) 0.75
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Genome maintenance mechanisms for preventing cancer. Nature (2001) 16.17
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol (2006) 9.58
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell (2010) 8.70
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
The DNA damage response and cancer therapy. Nature (2012) 5.25
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol (2011) 4.23
Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol (2007) 3.13
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res (2008) 2.70
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem (2007) 2.62
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 2.52
Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle (2011) 2.31
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res (2010) 1.82
Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep (2002) 1.80
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer (2011) 1.71
Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle (2010) 1.71
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) (2008) 1.70
Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle (2012) 1.66
Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther (2005) 1.65
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res (2010) 1.64
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. Oncogene (2004) 1.58
Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene (2007) 1.57
Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol (2008) 1.44
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer (2001) 1.42
DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene (2007) 1.40
Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev (2007) 1.34
A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol Biol Cell (2008) 1.34
Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol (2006) 1.20
Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer (1995) 1.15
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res (2009) 1.10
In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med (2008) 1.07
Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget (2010) 1.06
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget (2011) 1.05
AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget (2010) 0.91
Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle (2011) 0.90
In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol (2001) 0.87
Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. J Mammary Gland Biol Neoplasia (2011) 0.84
Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. Cell Cycle (2010) 0.81
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
Human CtIP promotes DNA end resection. Nature (2007) 10.63
RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell (2007) 9.25
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol (2005) 8.27
Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell (2003) 7.48
RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell (2009) 6.89
Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol (2006) 6.52
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol (2007) 5.78
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol (2006) 5.34
Checking on DNA damage in S phase. Nat Rev Mol Cell Biol (2004) 4.91
Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol (2003) 4.77
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol (2005) 4.62
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol (2011) 4.57
MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature (2003) 4.56
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol (2005) 4.54
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol (2002) 4.45
More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol (2011) 4.23
Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1. J Cell Biol (2005) 3.69
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell (2003) 3.58
E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol (2002) 3.46
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
Regulation of replication fork progression through histone supply and demand. Science (2007) 3.21
Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J (2004) 3.20
hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell (2005) 3.18
Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer (2007) 3.16
Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer (2004) 3.06
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet (2002) 3.00
ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell (2013) 2.99
The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet (2002) 2.97
Loss of Geminin induces rereplication in the presence of functional p53. J Cell Biol (2004) 2.97
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem (2008) 2.89
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol (2004) 2.63
Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol (2005) 2.63
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem (2003) 2.54
TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes. Cell (2012) 2.53
Human Asf1 regulates the flow of S phase histones during replicational stress. Mol Cell (2005) 2.51
Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell (2006) 2.45
Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) (2004) 2.39
Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J (2002) 2.39
HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nat Cell Biol (2009) 2.37
p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell (2006) 2.34
The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev (2002) 2.33
Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle (2011) 2.31
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res (2008) 2.27
ATM activation in normal human tissues and testicular cancer. Cell Cycle (2005) 2.25
Measuring elevated intracranial pressure through noninvasive methods: a review of the literature. J Neurosurg Anesthesiol (2013) 2.23
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21